DVA heads into its May 1 Q1 results carrying one of the more charged setups in health care services — a meaningful short position, a Berkshire anchor, and the shadow of February's explosive earnings gap.
Short sellers hold an elevated stake here. Short interest runs at 8.5% of free float, with days to cover at 8.6 — a structure that creates meaningful squeeze risk if the print surprises to the upside. That said, bears have been retreating in recent weeks. Short interest dropped 3.1% over the past week and has edged down roughly 0.4% over the month. The ORTEX short score of 65 reflects residual conviction rather than a fresh offensive. Borrow costs are low at 0.43% and have eased over the past month, while the lending market remains comfortably available — far from the tight conditions that would signal imminent squeeze pressure.
The bull-bear divide on DVA runs through reimbursement. Bulls point to the company's dominant 35% US market share in dialysis clinics, over 3,000 global facilities, and Berkshire Hathaway's 45.6% ownership stake as ballast — a vote of confidence that has stabilised the capital structure through multiple cycles. Bears focus on the structural fragility of the margin profile: Medicare accounts for roughly two-thirds of US revenue but a disproportionately small slice of profit, while the 10% of patients covered by commercial insurers drive most of the earnings. Any deterioration in that payer mix — or further Medicare reimbursement pressure — hits profits hard. The Street is broadly neutral; the analyst consensus is a Hold, with the mean price target at $152, barely above the current $152. Multiple target reductions from Barclays and TD Cowen over the past year reflect a gradual deflation in Street enthusiasm, though UBS raised its target to $190 in early February following the last earnings beat. Note that the most recent changes date from early February and should be treated as post-last-quarter context rather than fresh pre-print guidance.
The ownership structure is a story of its own. Berkshire holds 45.6% of shares and trimmed its stake by 1.66 million shares in the January reporting period — a notable move from a holder that previously accumulated aggressively. Combined with a cluster of C-suite selling on March 13 — the CFO sold nearly $6.5 million in combined transactions alongside the CLO and CCO — the insider register skews negative heading into the print, even if individual sale volumes were modest relative to total float. The 90-day net insider figure of +1.8 million shares reflects offsetting activity elsewhere in the period, but the concentrated March selling stands out.
The February earnings reaction is the data point no one forgets. DVA gapped 23% higher the day after Q4 results and held most of the gain over the following week, a move driven in part by short covering against an 8%-plus SI base. The Q1 print tests whether the company can extend that momentum — specifically, whether the payer mix and organic volume trends that spooked analysts through the second half of 2025 have stabilised, or whether the February gap was a one-quarter event.
See the live data behind this article on ORTEX.
Open DVA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
